CRIS Current Research Information System

PALLESCHI, MICHELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.850
NA - Nord America 1.151
EU - Europa 748
SA - Sud America 129
AF - Africa 54
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.936
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.105
VN - Vietnam 1.059
SG - Singapore 655
CN - Cina 587
IT - Italia 278
HK - Hong Kong 205
NL - Olanda 138
KR - Corea 107
BR - Brasile 100
DE - Germania 78
BD - Bangladesh 77
FR - Francia 58
FI - Finlandia 54
JP - Giappone 43
IN - India 40
CI - Costa d'Avorio 29
SE - Svezia 29
GB - Regno Unito 20
IE - Irlanda 20
ID - Indonesia 18
CA - Canada 17
MX - Messico 16
PH - Filippine 15
RU - Federazione Russa 15
AT - Austria 13
TH - Thailandia 12
SC - Seychelles 10
AR - Argentina 9
CH - Svizzera 9
PL - Polonia 9
EC - Ecuador 8
JO - Giordania 7
BE - Belgio 6
BG - Bulgaria 6
IQ - Iraq 6
CO - Colombia 4
CZ - Repubblica Ceca 4
ES - Italia 4
MA - Marocco 4
TW - Taiwan 4
BO - Bolivia 3
CR - Costa Rica 3
EG - Egitto 3
GH - Ghana 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
LT - Lituania 2
OM - Oman 2
PK - Pakistan 2
SA - Arabia Saudita 2
TG - Togo 2
TT - Trinidad e Tobago 2
UA - Ucraina 2
UZ - Uzbekistan 2
VE - Venezuela 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
CL - Cile 1
ET - Etiopia 1
HN - Honduras 1
IL - Israele 1
KN - Saint Kitts e Nevis 1
LB - Libano 1
LV - Lettonia 1
MY - Malesia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PY - Paraguay 1
SI - Slovenia 1
TR - Turchia 1
UY - Uruguay 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
ZA - Sudafrica 1
Totale 4.936
Salva come PNG Salva come JPEG
Città #
Singapore 494
Ho Chi Minh City 306
Hanoi 272
Hefei 249
San Jose 208
Hong Kong 193
Ashburn 156
Santa Clara 119
Seoul 101
Amsterdam 94
Dallas 85
Bologna 73
Beijing 49
Council Bluffs 48
Los Angeles 48
Boardman 39
Tokyo 37
Helsinki 36
Da Nang 35
New York 34
Lauterbourg 33
Haiphong 30
Abidjan 29
Bengaluru 25
Buffalo 25
Ha Long 23
Chandler 20
Dublin 20
Quận Bình Thạnh 20
Milan 19
Thái Nguyên 19
São Paulo 17
Nuremberg 16
Biên Hòa 15
Can Tho 15
Frankfurt am Main 15
Munich 15
Jakarta 14
Chicago 13
Hải Dương 13
Rome 13
Lappeenranta 12
Mexico City 11
Phủ Lý 11
Bắc Giang 10
Falkenstein 10
Ninh Bình 10
Princeton 10
Bắc Ninh 9
Düsseldorf 9
Redondo Beach 9
Vienna 9
Vinh 9
Vũng Tàu 9
Guangzhou 8
Xi'an 8
Amman 7
Montreal 7
Monzuno 7
Quận Một 7
Quận Phú Nhuận 7
Quận Sáu 7
Shanghai 7
Cesena 6
Quận Bảy 6
San Francisco 6
Sofia 6
Southend 6
Turin 6
Turku 6
Wilmington 6
Bern 5
Brooklyn 5
Brussels 5
Changsha 5
Florence 5
Hangzhou 5
Lấp Vò 5
Modena 5
Nam Định 5
Qingdao 5
Quận Tân Phú 5
Rimini 5
Rio de Janeiro 5
Salt Lake City 5
Thái Bình 5
Warsaw 5
Bạc Liêu 4
Can Giuoc 4
Chengdu 4
Fuzhou 4
Huế 4
London 4
Phoenix 4
Quezon City 4
Quảng Ngãi 4
Ravenna 4
Tam Bình 4
Tongling 4
Toronto 4
Totale 3.458
Salva come PNG Salva come JPEG
Nome #
Exploring the promoter regions of cancer predisposition genes in patients with triple-negative breast cancer reveals the presence of rare germline variants 351
Are BMI and Negative Hormone Receptors Prognostic Factors in HER2+ Early-stage Breast Cancer? 348
HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer 317
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 182
Transcriptomic profiling of circulating tumor cells from metastatic breast cancer patients reveals new hints in their biological features and phenotypic heterogeneity 181
An Italian Real-World Study Highlights the Importance of Some Clinicopathological Characteristics Useful in Identifying Metastatic Breast Cancer Patients Resistant to CDK4/6 Inhibitors and Hormone Therapy 179
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 170
Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis 162
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 155
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 152
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 148
Case Report: Analysis of Circulating Tumor Cells in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient 142
Case Report: Analysis of Plasma Extracellular Vesicles in a Triple Negative Spindle-Cell Metaplastic Breast Cancer Patient 131
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 128
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 123
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 121
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 120
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 117
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 115
Impressive long-term response with chemo-endocrine therapy in a premenopausal patient with metastatic breast cancer: A case report 109
Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial. 102
ANTIANGIOGENIC AGENTS ARE INEFFECTIVE TO INCREASE COMPLETE RESPONSE RATE IN MRCC. A META-ANALYSIS 100
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 88
Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer 87
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 85
Are we ready to use TMB in breast cancer clinical practice? 79
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 78
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 77
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 75
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 72
Atezolizumab plus Nab-paclitaxel in PD-L1–Positive TNBC—Letter 68
Immunotherapy: The end of the "dark age" for metastatic triple-negative breast cancer? 58
Pharmacological Prevention in Breast Cancer: Current Evidence, Challenges, and Future Directions 56
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 56
ROLE OF HPV VACCINATION AFTER CARCINOMA IN SITU OF CERVIX UTERI (CIN) IN REAL-WORLD PATIENTS 54
Hormonal Therapy For Endometriosis And The Risk Of Endometriosis-Associated Gynecologic Cancers: A Propensity Score-Adjusted Real-World Data Study 46
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 44
Germline BRCA-mutated metastatic breast cancer with positive hormone receptor 42
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 42
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough? 40
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 37
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report 34
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 33
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET 30
Precision medicine: PI3K targeting in advanced breast cancer 26
Eribulin in brain metastases of breast cancer: Outcomes of the EBRAIM prospective observational trial 25
Ribociclib and endocrine therapy in breast cancer 21
The promise of liquid biopsy in cancer: A clinical perspective 18
Multiparametric whole-body magnetic resonance imaging in breast cancer management: A prospective study 8
Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching 6
Corrigendum to “Association between chemotherapy use and prognosis in young patients with stage I-II ER+/HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching”(European Journal of Cancer, (2026), 242, C, (116818), (S095980492600599X), 10.1016/j.ejca.2026.116818) 3
Totale 5.041
Salva come PNG Salva come JPEG
Categoria #
all - tutte 11.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 11.849
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202257 0 0 0 4 4 0 3 2 0 9 24 11
2022/2023128 5 11 5 16 7 13 2 8 33 4 9 15
2023/2024143 1 6 1 5 2 7 9 6 66 17 11 12
2024/2025976 35 119 77 68 156 58 40 31 7 89 73 223
2025/20263.737 712 453 424 281 253 69 348 157 535 217 167 121
Totale 5.041